Bisphosphonate Induces Remission of Refractory Osteolysis in Langerhans Cell Histiocytosis
- 1 November 2002
- journal article
- case report
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 17 (11) , 1926-1928
- https://doi.org/10.1359/jbmr.2002.17.11.1926
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Pamidronate for Bone Pain from Osteolytic Lesions in Langerhans'-Cell HistiocytosisNew England Journal of Medicine, 2001
- Treatment of Langerhans Cell Histiocytosis With PamidronateJournal of Pediatric Hematology/Oncology, 2001
- Alendronate Is a Specific, Nanomolar Inhibitor of Farnesyl Diphosphate SynthaseArchives of Biochemistry and Biophysics, 2000
- Farnesol and Geranylgeraniol Prevent Activation of Caspases by Aminobisphosphonates: Biochemical Evidence for Two Distinct Pharmacological Classes of Bisphosphonate DrugsMolecular Pharmacology, 1999
- Expanding role of bisphosphonate therapy in childrenThe Journal of Pediatrics, 1999
- AN UPDATE ON CLONALITY, CYTOKINES, AND VIRAL ETIOLOGY IN LANGERHANS CELL HISTIOCYTOSISHematology/Oncology Clinics of North America, 1998
- The Role of Bisphosphonates for the Treatment of Bone Disease in Multiple MyelomaLeukemia & Lymphoma, 1998
- A multicentre retrospective survey of Langerhans' cell histiocytosis: 348 cases observed between 1983 and 1993. The French Langerhans' Cell Histiocytosis Study Group.Archives of Disease in Childhood, 1996
- Long-term effects of intravenous pamidronate in fibrous dysplasia of boneThe Lancet, 1994